1. Zions Bancorporation, Salt Lake City, Utah; to merge with GB Bancorporation, San Diego, California, and thereby indirectly acquire Grossmont Bank, San Diego, California, and up to 24.9 percent of the voting shares of Rancho Vista National Bank, Vista, California, and up to 24.9 percent of the voting shares of Pacific Commerce Bank, Chula Vista, California.

Board of Governors of the Federal Reserve System, August 22, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–22788 Filed 8-26-97; 8:45 am]

BILLING CODE 6210-01-F

GENERAL SERVICES ADMINISTRATION

Federal Acquisition Policy Division, FAR Secretariat, Cancellation of a Standard Form

AGENCY: General Services Administration.

ACTION: Notice.

SUMMARY: The Federal Acquisition Regulations eliminated the need for Standard Form 119, Statement of Contingent or Other Fees removing the regulations that required its use. Therefore, SF 119 is cancelled.

FOR FURTHER INFORMATION CONTACT: Mr. Ralph DeStefano, (202) 501–1758.

EFFECTIVE DATE: August 27, 1997.

Dated: August 21, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms Management Officer.

[FR Doc. 97–22815 Filed 8–26–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Health Care Policy and Research

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Agency for Health Care Policy and Research, HHS.

ACTION: Notice.

SUMMARY: This notice announces the Agency for Health Care Policy and Research's (AHCPR) intention to request the Office of Management and Budget (OMB) to allow a proposed information collection project of ''A Survey of Clinical Decision Support Systems (CDSS).'' In accordance with the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)), AHCPR invites the public to comment on this proposed information collection.

DATES: Comments on this notice must be received by September 26, 1997.

ADDRESSES: Written comments should be submitted to the OMB Desk Officer at the following address: Allison Eydt, Human Resources and Housing Branch, Office of Information and Regulatory Affairs, OMB; New Executive Office Building, Room 10235; Washington, 20503.

All comments will become a matter of public record.

FOR FURTHER INFORMATION CONTACT: Ruth A. Celtnieks, AHCPR Reports Clearance Officer, (301) 594–1406, ext. 1497.

SUPPLEMENTARY INFORMATION:

Proposed Project

''A Survey of Clinical Decision Support Systems (CDSS).'' The AHCPR intends to conduct a survey to gather the opinions of front-line physicians, nurses, and medical information systems personnel regarding the use, appropriateness, and effectiveness of clinical decision support systems (CDSS); and to determine how well clinical practice guidelines are integrated into these systems.

This proposed study is a part of a larger project to identify and describe CDSS currently available in the health market, and to assess the use of CDSS by health care providers in diagnosing and treating patients as well as identifying barriers to using CDSS. It will assess if, and how, clinical practice guidelines are being successfully integrated into CDSS and will identify any changes needed for the guidelines to play a more significant role in future systems.

The information collected will indicate:

- If, and how, CDSS and clinical practice guidelines impact the treatment and outcome of patient care;
- What, if any, are the barriers to CDSS and the guidelines from being accepted by health care providers;
- What types of health care personnel are utilizing guidelines in the treatment of their patients and what types of health care personnel could benefit from such products; and
- Assess how successfully guidelines are being integrated into CDSS and their effectiveness when accessed as part of CDSS; and what needs to be modified/changed to facilitate the use of guidelines in CDSS.

The respondents' comments will provide AHCPR with information on (1) if and how CDSS may improve the quality and outcome of care and promote cost-containment, and (2) whether and how to better incorporate guidelines into the development and use of CDSS.

Method of Collection

The survey will be conducted using a computerized telephone interview system (CATI). Burden estimates follow:

Number of Respondents: 80.

Number of Surveys Per Respondent: 1.

Average Burden Per Respondent: 25–30 minutes.

Estimated Total Burden: 40 hours.

Request for Comments

Comments are invited on: (a) The necessity of the proposed collection; (b) the accuracy of the Agency's estimate of burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Copies of these proposed collection plans and instruments can be obtained from the AHCPR Reports Clearance Officer (see above).

Dated: August 13, 1997.

John M. Eisenberg,

Administrator.

[FR Doc. 97–22315 Filed 8–26–97; 8:45 am]

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Health Care Policy and Research

Contract Review Meeting

In accordance with Section 10(a) of the Federal Advisory Committee Act (5 U.S.C. Appendix 2), announcement is made of the following technical review committee to meet during the month of September 1997:

Name: Committee on the Agency for Health Care Policy and Research, Small Business Innovation Research (SBIR) Program—Phase II.

Date and Time: September 5, 1997, 9:00 a.m.—3:00 p.m.

Place: Agency for Health Care Policy and Research, 2101 East Jefferson Street, 5th Floor, Conference Room, Rockville, MD 20852.

This meeting will be closed to the public.

Purpose: The Technical Review Committee's charge is to provide, on behalf

of the Agency for Health Care Policy and Research (AHCPR) Contracts Review Committee, recommendations to the Administrator, AHCPR, regarding the technical merit of contract proposals submitted in response to a specific Request for Proposals regarding the Small Business Innovation Research (SBIR) Program.

The purpose of this contract is to continue the research that was initiated in Phase I of these SBIR contracts.

Agenda: The Committee meeting will be devoted entirely to the technical review and evaluation of contract proposals submitted in response to the above referenced Request for Proposals. The Administrator, AHCPR, has made a formal determination that this meeting will not be open to the public. This action is necessary to protect the free and full exchange of views in the contract evaluation process and safeguard confidential proprietary information, and personal information concerning individuals associated with the proposals that may be revealed during the meeting. This action is taken in accordance with section 10(d) of the Federal Advisory Committee Act, 5 U.S.C., Appendix 2, 5 U.S.C. 522(b)(c)(6), 41 CFR 101–6.1023 and Department procurement regulations, 48 CFR 315.604(d).

Anyone wishing to obtain information regarding this meeting should contact Charles Darby, Center for Quality Measurement and Improvement, Agency for Health Care Policy and Research, 2101 East Jefferson Street, Suite 502, Rockville, Maryland 20852, 301/594–1349, X1316.

Dated: August 20, 1997.

John M. Eisenberg,

Administrator.

[FR Doc. 97–22785 Filed 8–26–97; 8:45 am]

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N–0071]

Amirul Islam; Final Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (the act) permanently debarring Mr. Amirul Islam, 120 Adams St., Deer Park, NY 11729, from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Mr. Islam was convicted of a felony under Federal law for conduct relating to the regulation of a drug product under the act. Mr. Islam has waived his opportunity for a hearing concerning this action.

EFFECTIVE DATE: August 27, 1997.

ADDRESSES: Application for termination of debarment to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Leanne Cusumano, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION:

I. Background

Mr. Amirul Islam, a former vice president of technical services for Halsey Drug Co., Inc., (Halsey) and supervisor of Halsey's Quality Control Laboratory, pled guilty to, and on October 19, 1994, was sentenced for, obstructing an agency proceeding, a Federal felony under 18 U.S.C. 1505. The basis for this conviction was as follows: On or about August 29, 1989, Mr. Islam gave FDA inspectors a raw material inventory card for fenoprofen calcium which he knew to be false. The inventory card stated that Halsey had received 50 kilograms of fenoprofen calcium on September 11, 1987. In fact, Halsey had received only half that amount. Mr. Islam knew that the purpose of the falsified inventory card was to conceal from FDA the fact that Halsey did not have enough raw material from the September 11, 1987, shipment to manufacture pilot batches in the sizes represented in abbreviated new drug applications (ANDA's) for fenoprofen calcium 200 milligram (mg) capsules, fenoprofen calcium 300 mg capsules, and fenoprofen calcium 600 mg tablets.

Mr. Islam is subject to debarment based on a finding, under section 306(a) of the act (21 U.S.C. 355a(a)), that he was convicted of a felony under Federal law for conduct relating to the regulation of a drug product. Mr. Islam's conduct related to the regulation of a drug product because, in presenting false raw material inventory records, he obstructed FDA's regulation of generic drugs by representing that the ANDA's submitted by Halsey were true in all material respects.

FDA initiated debarment proceedings against Mr. Islam on or about May 15, 1995. A person subject to debarment is entitled to an opportunity for an agency hearing on disputed issues of material fact under section 306(i) of the act, but Mr. Islam waived his opportunity for a hearing and any contentions concerning his debarment by letter received by FDA on April 22, 1997.

II. Findings and Order

Therefore, the Director, Center for Drug Evaluation and Research, under section 306(a)(2)(B) of the act, and under authority delegated to her (21 CFR 5.99), finds that Mr. Amirul Islam has been convicted of a felony under Federal law for conduct relating to the regulation of a drug product.

As a result of the foregoing findings and based on his notification of acquiescence, Mr. Amirul Islam is permanently debarred from providing services in any capacity to a person with an approved or pending drug product application under sections 505, 507, 512, or 802 of the act (21 U.S.C. 355, 357, 360b, or 382), or under section 351 of the Public Health Service Act (42 U.S.C. 262), effective August 27, 1997 (sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21 U.S.C. 321(dd))). Any person with an approved or pending drug product application who knowingly uses the services of Mr. Islam, in any capacity, during his period of debarment, will be subject to civil money penalties (section 307(a)(6) of the act (21 U.S.C. 335b(a)(6))). If Mr. Islam, during his period of debarment, provides services in any capacity to a person with an approved or pending drug product application, he will be subject to civil money penalties (section 307(a)(7) of the act). In addition, FDA will not accept or review any ANDA's or abbreviated antibiotic drug applications submitted by or with the assistance of Mr. Islam during his period of debarment.

Any application by Mr. Islam for termination of debarment under section 306(d) of the act should be identified with Docket No. 95N–0071 and sent to the Dockets Management Branch (address above). All such submissions are to be filed in four copies. The public availability of information in these submissions is governed by 21 CFR 10.20(j). Publicly available submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: August 19, 1997.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 97–22704 Filed 8–26–97; 8:45 am]

BILLING CODE 4160–01–F